Program
QHRD106
A development code. Also written as “QHRD106 Injection”, “QHRD106 Injection (Low-dose group)” and “QHRD106 Injection (Middle-dose group)”.
Its studies are mostly in Ischemic Stroke, led by Changzhou Qianhong Bio-pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changzhou Qianhong Bio-pharma | 31 open or running | phase 2since Feb 1, 2026 | Apr 16, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2024First studies: 2 phase 1 studies in Ischemic StrokeFirst studyNCT06380699, NCT06388772
- Feb 1, 2026Phase 2 study in Ischemic StrokePhase 2 reachedNCT07396337 · 320 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07396337Ischemic Stroke · China | 2 | Recruiting | Oct 31, 2026 | 320 |
| NCT06388772Ischemic Stroke · China | 1 | Completed | Jul 22, 2022 | 74 |
| NCT06380699Ischemic Stroke · China | 1 | Completed | Nov 16, 2023 | 56 |
How it is read
Names in the registry
- “QHRD106 Injection”, 2 entries
- “QHRD106 Injection (Low-dose group)”, 1 entry
- “QHRD106 Injection (Middle-dose group)”, 1 entry
- “QHRD106 Injection (High-dose group)”, 1 entry
Codes read as this program: QHRD106.
Conditions, from the studies’ own filings
- Ischemic Stroke, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.